Managed Care

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Retrieved on: 
Sunday, April 7, 2024
Research, FDA, Clinical Trials, Cardiology, Biotechnology, Managed Care, Health, Pharmaceutical, Science, Blood pressure, Medication, Indapamide, Risk, Patient, Month, SBP, ABPM, American College, Olmesartan, Injection, Safety, RNA interference, Therapy, AGT, ACC, Amlodipine, Cardiomyopathy, Hypertension, Pharmaceutical industry

Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.

Key Points: 
  • Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.
  • The results were presented today as a late-breaking clinical trial at the 2024 American College of Cardiology (ACC) Annual Scientific Session.
  • The Company previously announced positive topline results from the KARDIA-2 study in March 2024.
  • “Although many effective oral treatments are available, a large proportion of patients with hypertension are not managed to guideline-recommended targets.

Tempus Introduces Workspaces into its Lens Data Analytics Platform

Retrieved on: 
Saturday, April 6, 2024
Health Technology, Telemedicine, Virtual Medicine, Data Management, Other Health, Technology, Practice Management, Apps, Applications, Managed Care, General Health, Hospitals, Artificial Intelligence, Other Technology, Software, Networks, Health, Mobile, Wireless, Intelligence, Workspace, Medicine, HLA, Research, Genotype, Prevalence, AI

Tempus, a leader in artificial intelligence and precision medicine, is broadly introducing its new Workspaces feature in the Lens platform.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, is broadly introducing its new Workspaces feature in the Lens platform.
  • Workspaces is a private, coding-based cloud environment designed to unblock research and accelerate innovation.
  • This new interface provides researchers a frictionless workflow for surfacing critical insights to power scientific discovery and development.
  • Lens is already trusted by nearly 100 institutions, including healthcare systems and biopharma companies, to power research that improves patient outcomes.

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024

Retrieved on: 
Saturday, April 6, 2024
Mental Health, Research, Neurology, Clinical Trials, Biotechnology, Managed Care, Health, Pharmaceutical, Science, TEVA, De novo, Patient, Interview, NNH, Tardive dyskinesia, Congress, Medication, Risperidone, International, Risk, NNT, Caregiver, Safety, HCP, Emotion, Teva Pharmaceuticals, Health professional, Data wrangling, Death, Lais, Teva, FDA, Olanzapine, SIRS, Perception, Physician, Schizophrenia International Research Society, Persistence

The data were presented at the 2024 Congress of the Schizophrenia International Research Society (SIRS) taking place from April 3-7, 2024 in Florence, Italy.

Key Points: 
  • The data were presented at the 2024 Congress of the Schizophrenia International Research Society (SIRS) taking place from April 3-7, 2024 in Florence, Italy.
  • “Schizophrenia is a complex mental health condition where the treatment needs and preferences of those living with it may evolve over time.
  • In the patient survey, approximately 20 patients and 19 caregivers completed a 60-minute interview regarding the use of LAIs in schizophrenia.
  • Below is the full set of data presented by Teva at SIRS 2024.

Tempus Announces 18 Abstracts Accepted For Presentation at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Friday, April 5, 2024
Research, Managed Care, Pharmaceutical, Oncology, Data Management, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, Mutation, Survival, ESR1, Intelligence, Progression-free survival, Patient, NGS, DNA, MD, Medicine, Abstract, AACR, TRM, Clonal hematopoiesis, AIS, Liquid biopsy, Enzyme inhibitor, Annual general meeting, Medical imaging

Tempus, a leader in artificial intelligence and precision medicine, today announced 18 abstracts were accepted for presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 5-10, in San Diego, California.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced 18 abstracts were accepted for presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 5-10, in San Diego, California.
  • Tempus researchers will demonstrate how the company’s AI-enabled precision medicine platform collects and analyzes high-quality, multimodal datasets to advance cancer research.
  • “We look forward to presenting 18 abstracts at AACR this year, demonstrating the breadth and depth of our research both at Tempus and with our biopharma collaborators,” said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus.
  • These preliminary findings suggest that xM used for TRM can identify patients with ESR1m and poor response on AI who may benefit from switching therapy.

Maximus Declares Quarterly Cash Dividend of $0.30 per Share

Retrieved on: 
Friday, April 5, 2024
Technology, Managed Care, General Health, Hospitals, Payments, Health, Health Technology, Health Insurance, Other Technology, Telemedicine, Virtual Medicine, Software, Other Health, Networks, Internet, Mobile, Wireless, Data Management, Practice Management, MMS

Maximus (NYSE: MMS), a leading provider of government services worldwide, announced today that its Board of Directors has approved a quarterly cash dividend of $0.30 per share, payable on May 31, 2024, to shareholders of record on May 15, 2024.

Key Points: 

Maximus (NYSE: MMS), a leading provider of government services worldwide, announced today that its Board of Directors has approved a quarterly cash dividend of $0.30 per share, payable on May 31, 2024, to shareholders of record on May 15, 2024.

AltPep Study Published in Nature Journal, Scientific Reports, Further Affirms Potential of Blood Test to Detect Alzheimer's Disease

Retrieved on: 
Friday, April 5, 2024
Research, Neurology, Publishing, Communications, Clinical Trials, Biotechnology, Managed Care, Health, Science, Plasma, Scientific Reports, Patient, University, Amyloid, Neuropathology, MCI, Pharmaceutical industry

The data, consistent with an earlier study , further support the potential value of the SOBA-AD test as a promising blood-based tool for the selective detection and confirmation of AD.

Key Points: 
  • The data, consistent with an earlier study , further support the potential value of the SOBA-AD test as a promising blood-based tool for the selective detection and confirmation of AD.
  • The SOBA-AD blood test targets toxic soluble oligomers, an early molecular trigger of amyloid diseases, with the ultimate goal of identifying patients with the disease years before symptoms manifest.
  • The SOBA-AD blood test identified AD patients from cognitively unimpaired (CU) subjects with 100% sensitivity, >95% specificity, and >98% area under the curve (95% CI 0.95-1.00).
  • These results for our simple SOBA-AD blood test support the goal of earlier, pre-symptomatic detection of patients with AD.

Lively HSA Account Holders Boast 2x Investing and 17% Higher Account Balances Than Industry Average

Retrieved on: 
Thursday, April 4, 2024
Technology, Professional Services, Managed Care, Other Health, Health, Health Insurance, Asset Management, Software, Fintech, Human Resources, Finance, Health savings account, Mental health, Customer, Human services, Investment, Plasma protein binding, Habit, HSA, Multimedia

Lively, Inc., a top-rated health and lifestyle benefits platform* known for creating the modern Health Savings Account (HSA), today announces the release of its sixth annual HSA Snapshot report, which tracks HSA account holders’ saving, spending, and investing.

Key Points: 
  • Lively, Inc., a top-rated health and lifestyle benefits platform* known for creating the modern Health Savings Account (HSA), today announces the release of its sixth annual HSA Snapshot report, which tracks HSA account holders’ saving, spending, and investing.
  • Lively’s annual account balance of funded accounts is $4,885, which is 17% higher than the industry average of $4,177.
  • Investments drive HSA balance growth and Lively account holders invest nearly 2x the industry average.
  • Despite increased withdrawal activity, Lively account holders retain more of their HSA assets than the industry average at 25% compared to 23% industry wide.

Quad Announces New Predictive Model of Consumer Attitudes in Health Insurance

Retrieved on: 
Thursday, April 4, 2024
Telemedicine, Virtual Medicine, Software, Artificial Intelligence, Hospitals, Professional Services, Technology, Nursing, Search Engine Marketing, Managed Care, Digital Marketing, Other Communications, Data Analytics, Marketing, Advertising, Health, Content Marketing, Communications, Health Insurance, Media, Intelligence, Research, Acquisition, Utility, Insurance, Senior, Thought, Accessibility, Quad (company), Quad, Risk management

The model is based on nationally representative, primary research about what consumers value most from their health insurance.

Key Points: 
  • The model is based on nationally representative, primary research about what consumers value most from their health insurance.
  • The research, which is detailed in Quad’s new report, “Tapping the Power of Consumer Attitudes,” uncovered three distinct segments for consumer attitudes.
  • ”Quad’s predictive model adds a new dimension to personalized, health insurance marketing,” Hickman continued “We can now create much more direct consumer connections by precisely aligning health insurance marketing messages – and even customer service scripts and product development – with what consumers have told us matters most to them.
  • For a summary of the report, “Tapping the Power of Consumer Attitudes,” or to request a full copy, visit this link or send an email to [email protected] .

Verato names Andy Dé as Chief Marketing Officer

Retrieved on: 
Thursday, April 4, 2024
Data Management, Technology, Professional Services, Managed Care, Other Health, Health, Health Technology, Health Insurance, Data Analytics, Software, Hospitals, Tableau, GTM, GM, Growth, Science, Blue, Business, Artificial intelligence, University, Triple accreditation, Tableau Software, Harvard Business School, SAP, CPG, GE HealthCare, MBA, Engineering, CMO, Marketing, Alteryx, Management

Verato , the identity experts for healthcare, today announced the appointment of Andy Dé to the role of Chief Marketing Officer (CMO).

Key Points: 
  • Verato , the identity experts for healthcare, today announced the appointment of Andy Dé to the role of Chief Marketing Officer (CMO).
  • Dé will oversee the company’s go-to-market (GTM) strategy, planning and execution in his role leading the global marketing organization reporting to Clay Ritchey, Chief Executive Officer (CEO).
  • “I am humbled and honored to join Verato and bring my passion for building, transforming and growing world-class, high-performing global marketing teams to drive the continued rapid growth of adoption of Verato’s industry leading hMDM solutions,” said Andy Dé, CMO at Verato.
  • “I am thrilled to welcome Andy to the Verato team,” said Clay Ritchey, CEO of Verato.

Rockwell Medical Expands Global Distribution in the Dominican Republic and Bermuda

Retrieved on: 
Thursday, April 4, 2024
Packaging, Logistics, Supply Chain Management, Manufacturing, Other Health, Public Relations, Investor Relations, Marketing, Communications, Medical Devices, Social Media, Small Business, Human Resources, Science, Other Transport, Professional Services, Trucking, Medical Supplies, Health, Transport, Managed Care, Other Science, General Health, Research, Rockwell Medical, The Company, AMI, Peritoneal dialysis, Senior, Dialysis, Vaccine

Rockwell Medical signed a five-year distributor agreement with BioNuclear through which BioNuclear may import, sell, promote and distribute Rockwell Medical's hemodialysis concentrates products within the Dominican Republic.

Key Points: 
  • Rockwell Medical signed a five-year distributor agreement with BioNuclear through which BioNuclear may import, sell, promote and distribute Rockwell Medical's hemodialysis concentrates products within the Dominican Republic.
  • The amended distribution agreement between Rockwell Medical and AMI expands the list of hemodialysis products that AMI is purchasing from the Company, includes purchasing commitments, and generates a profit margin consistent with Rockwell Medical's gross margin guidance for 2024.
  • "This updated distribution agreement with Rockwell Medical affords us the ability to serve and deliver more high-quality, life-sustaining products to the fragile dialysis population in Bermuda."
  • "The global reach of our hemodialysis concentrates products continues to grow," said Tim Chole , Senior Vice President, Sales and Marketing at Rockwell Medical.